Lilly and American Migraine Foundation Announce $1 million grant for launch of first patient registry to advance R&D in migraine
Data from the registry will be made accessible to all researchers, with grant applications available for high-priority projects.
Eli Lilly and the American Migraine Foundation have announced that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
Migraine is the third-most prevalent and sixth-most disabling medical disorder in the world, and it is the leading cause of all disability attributed to neurological diseases worldwide. Other primary and secondary headache disorders are also highly prevalent and cause substantial burden for people with these diseases, including impaired quality of life and financial cost.
Through this registry, the American Migraine Foundation aims to establish repositories and enroll patients with primary and secondary headache disorders to collect imaging data, genetics information and biologic samples. The American Migraine Foundation will also work to establish and train a larger network of investigative sites to enroll subjects, submit data and access all collected data for specific studies. Data from the registry will be made accessible to all researchers, with grant applications available for high-priority projects.
"We are enormously grateful for the vision and very generous support from Lilly to help the American Migraine Foundation build and sustain a patient registry and biorepository for migraine and other headache disorders," said American Migraine Foundation Chairman Dr David Dodick. "We believe the knowledge gained from this registry and the potential to identify clinical, laboratory, imaging and genetic biomarkers will usher in an era of precision medicine and generate new targets for generations of patients to come."
As a platinum sponsor, Lilly will serve as a member of the Corporate Registry Roundtable, working with the American Migraine Foundation and other members to propose topics and analysis areas for the registry, which will be approved by the ARMR Scientific Review Board.
"Despite the prevalence and overwhelming impact they cause, migraine and other headache disorders historically are some of the most underfunded areas of clinical research," said Dr. Robert Conley, Distinguished Lilly Scholar and leader of Lilly's pain development platform. "We are proud to support the American Migraine Foundation's efforts to establish a registry that will allow researchers to evaluate and compare real-world data that can help transform research in headache disorders, and ultimately help healthcare providers improve outcomes for people living with these devastating disorders."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance